George S. Han

Family Medicine
315 W 57th St
New York, NY 10019

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 93 publications

The Future of Psoriasis Care.

The Future of Psoriasis Care.

Journal: Cutis
Published: May 15, 2026

The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains.

The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains.

Journal: Dermatology online journal
Published: April 07, 2026

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026

Letter From the New Editor-in-Chief.

Letter From the New Editor-in-Chief.

Journal: Journal of psoriasis and psoriatic arthritis
Published: February 25, 2026

More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis.

More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis.

Journal: Journal of drugs in dermatology : JDD
Published: December 02, 2025

Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure.

Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure.

Journal: Dermatology and therapy
Published: July 02, 2025

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.

Journal: JAMA dermatology
Published: June 18, 2025

IL-17C as a Driver of Inflammation in Psoriasis.

IL-17C as a Driver of Inflammation in Psoriasis.

Journal: Advances in therapy
Published: May 28, 2025

The Post-PASI Era: Considering Comorbidities to Select Appropriate Systemic Psoriasis Treatments.

The Post-PASI Era: Considering Comorbidities to Select Appropriate Systemic Psoriasis Treatments.

Journal: Cutis
Published: March 19, 2025

A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel.

A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel.

Journal: Journal of drugs in dermatology : JDD
Published: February 06, 2025

Palmoplantar Pustulosis: Therapy Update

Palmoplantar Pustulosis: Therapy Update

Journal: Journal of drugs in dermatology : JDD
Published: August 02, 2024

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.

Journal: Journal of drugs in dermatology : JDD
Published: August 02, 2024
Showing 1-12 of 93

Last Updated: 09/26/2026